Spero Therapeutics (SPRO) Other Non-Current Liabilities (2016 - 2022)

Spero Therapeutics (SPRO) has 7 years of Other Non-Current Liabilities data on file, last reported at $100000.0 in Q3 2022.

• For the quarter ending Q3 2022, Other Non-Current Liabilities changed N/A year-over-year to $100000.0; the trailing twelve-month figure through Sep 2022 stood at $100000.0 (changed N/A YoY), and the FY2021 full-year result was $802000.0, changed N/A from the prior year.
• Other Non-Current Liabilities for Q3 2022 stood at $100000.0, roughly flat from $100000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $802000.0 in Q4 2021 and bottomed at $100000.0 in Q2 2022.
• The 5-year median for Other Non-Current Liabilities is $223000.0 (2018), against an average of $247000.0.
• The widest annual swing landed in 2018, when Other Non-Current Liabilities increased 11.5%; it then dropped 10.31% in 2019.
• A 5-year view of Other Non-Current Liabilities shows it stood at $223000.0 in 2018, then dropped by 10.31% to $200000.0 in 2019, then changed by 0.0% to $200000.0 in 2020, then jumped by 301.0% to $802000.0 in 2021, then tumbled by 87.53% to $100000.0 in 2022.
• The last three Other Non-Current Liabilities figures came in at $100000.0 (Q3 2022), $100000.0 (Q2 2022), and $802000.0 (Q4 2021), per Business Quant data.

Peer Comparison